Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, proudly concludes its most significant presence to date at the European Wound Management Association (EWMA) 2025, held March 26-28 in Barcelona, Spain.
EWMA Conference is Europe’s premier global event in wound care innovation, and this year’s edition brought together over 6,400 participants, including experts from more than 90 countries and 150+ leading industry exhibitors. Aurealis Therapeutics was proud to be part of this international scientific community gathering, contributing through four key presentations, making our most significant presence at EWMA to date.
Representing Aurealis Therapeutics were CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake, along with distinguished Key Speaker Professor Alberto Piaggesi, who shared Aurealis’ exciting Phase 2 clinical trial investigator data results of AUP-16 – a novel multi-targeting cell and gene therapy for non-healing Diabetic Foot Ulcers (DFU).
Aurealis Therapeutics’ scientific and business development participation at EWMA included:
- EWMA Innovation Forum
Presentation: Circumventing Funding Challenges in Wound Care – The Aurealis Business Case
Speaker: Laurent Décory
Presented Aurealis’ strategy from disruptive product design, to business model, evidence generation and fund raising in a challenging environment. - Session on Ongoing Diabetic Foot RCTs
Presentation: The DIAMEND/ESMERALD Studies (Aurealis)
Speaker: Professor Alberto Piaggesi
Within the Diabetic Foot Committee meeting, introduced Aurealis’ DFU clinical programs and collaboration with Pisa University Hospital, emphasizing current DIAMEND Phase 2 clinical trial and recently submitted ESMERALD clinical study. - E-Poster Presentation on Diabetic Foot
Presentation: A randomized controlled Phase 2 trial to evaluate multi-factorial gene therapy AUP1602-C in the management of non-healing diabetic foot ulcer
Speaker: Professor Alberto Piaggesi
Access the e-poster here. - Aurealis Therapeutics’ Industry-Sponsored Symposium
Title: AUP-16: A novel four-in-one multi-targeting therapy for non-healing Diabetic Foot Ulcers
Speakers: Laurent Décory, Haritha Samaranayake, and Professor Alberto Piaggesi
The symposium brought together 35 participants, including clinicians, investigators, KOLs, experts from MedTech and Pharmaceutical companies for an in-depth look at Aurealis’ multi-targeting technology, the study design and latest data from DIAMEND Phase 2 clinical trial in DFUs. Participants expressed strong interest in the study design and results, the innovative mechanism of action of AUP-16, and the potential for future collaboration.
Professor Alberto Piaggesi’s contributions across the three sessions in which he participated, as well as his own session on the Diabetic Foot Ulcer Committee, were key in delivering Aurealis’ clinical messages and latest advancements. We are deeply grateful for his role as Global Coordinating Investigator and the confidence he expressed in our clinical data and development approach.
All in all, Aurealis Therapeutics participation at EWMA 2025 was a success. “This has been our most successful EWMA to date, both from a scientific and business development standpoint,” said COO Laurent Décory. “We are heading towards exciting times at the company, and we look forward to our following participations, in this case, the Symposium on Advanced Wound Care (SAWC Spring) 2025, 30 April – 3 May in Texas, USA.”
About AUP-16
AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF-2, bFGF), interleukin-4 (IL-4) and macrophage colony stimulating factor (CSF-1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers or other ulcer types). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage company developing scalable and low COGS multi-target cell and gene therapies allowing to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. Aurealis modular gene therapy platform consists of non-pathogenic lactic acid bacterium Lactococcus cremoris, genetically engineered to produce and release multiple human therapeutic proteins in the body: cytokines, chemokines, growth factors, antibody fragments. These living bacterium act as millions of nanoscale bioreactors at the site of the disease, allowing multi-targeting as one product, to treat multifactorial diseases. Aurealis pipeline includes Chronic Wounds (AUP-16, ongoing Phase 2), Oncology (AUP-55, pre-clinical stage), Inflammation (AUP-60, discovery stage).
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
